Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423849 | 0.91 | PDGFRB (0.54) | PDGFRBKDRSAE1UBA2SMN1; SMN2 | |
| SCHEMBL441291 | 0.87 | CA1 (0.55) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL15932600 | 0.87 | RAB9A (0.55) | PDGFRBKDRSAE1UBA2CA1 | |
| SCHEMBL423204 | 0.86 | PDGFRB (0.61) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL418813 | 0.86 | MEN1 (0.59) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL424231 | 0.86 | RAB9A (0.55) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL60398 | 0.85 | KDR (0.50) | PDGFRBKDRSAE1UBA2CA1 | |
| SCHEMBL59635 | 0.84 | KDR (0.60) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL15565987 | 0.84 | CA1 (0.52) | PDGFRBKDRSAE1UBA2CA1 | |
| SCHEMBL424884 | 0.83 | ALDH1A1 (0.62) | PDGFRBKDRSAE1UBA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-9695181-B2 | Hydroximic acid derivatives and medical applications therof | Feng, Zixia (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695181-B2 | Hydroximic acid derivatives and medical applications therof | Feng, Zixia (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20160176879-A1 | Novel Hydroximic Acid Derivative and Medical Application Thereof | ZENG, ZIXIA (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20160176879-A1 | Novel Hydroximic Acid Derivative and Medical Application Thereof | ZENG, ZIXIA (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-04 | — | — | US | disclosed |
| CN-103396417-B | Novel hydroxamic acid derivative and medical application thereof | FENG ZIXIA | 2015-02-04 | — | — | CN | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1633710-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | Abbott Laboratories (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004108672-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176879-A1 | Novel Hydroximic Acid Derivative and Medical Application Thereof | HCAR2, HCAR1, HDAC5 | PDGFRB 20/4885KDR 25/4885SAE1 2999/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | PDGFRB 280/4885KDR 511/4885SAE1 4456/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | PDGFRB 549/4885KDR 724/4885SAE1 4084/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | PDGFRB 579/4885KDR 970/4885SAE1 3387/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PDGFRB 295/4885KDR 494/4885SAE1 4303/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | PDGFRB 631/4885KDR 800/4885SAE1 3363/4885 |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | PDGFRB 579/4885KDR 970/4885SAE1 3387/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PDGFRB 295/4885KDR 494/4885SAE1 4303/4885 |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | PDGFRB 579/4885KDR 970/4885SAE1 3387/4885 |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BTK, SYK, LCK | PDGFRB 579/4885KDR 970/4885SAE1 3387/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | PDGFRB 592/4885KDR 527/4885SAE1 3486/4885 |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | PDGFRB 579/4885KDR 970/4885SAE1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.